| Aug 13 |
Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
|
| Aug 12 |
Checkpoint Therapeutics GAAP EPS of -$0.18 beats by $0.10
|
| Aug 12 |
Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates
|
| Jul 25 |
Checkpoint spikes as cancer drug undergoes FDA review
|
| Jul 25 |
Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
|
| Jul 15 |
Checkpoint, GC Cell to evaluate combo cancer therapy
|
| Jul 15 |
GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research
|
| Jul 2 |
Checkpoint resubmits FDA application for cosibelimab
|
| Jul 2 |
Checkpoint Therapeutics Resubmits Biologics License Application for Cosibelimab, Launches $12 Million Direct Share Offering
|
| Jul 2 |
Checkpoint Therapeutics looks to raise $12M through direct offering
|
